VIP and Mental deterioration: This suggests that inhibition of hippocampal LTP by VIP may be neuroprotective in conditions associated with aberrant synaptic plasticity, and that VPAC1 receptor ligands may constitute more efficient and safer drugs to treat cognitive decline in the aging or epileptic.